09-814
Anti-dimethyl-Arginine Antibody, asymmetric (ASYM25)
serum, from rabbit
Sinónimos:
dimethyl-arginine, asymmetric
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
About This Item
Código UNSPSC:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Productos recomendados
origen biológico
rabbit
Nivel de calidad
forma del anticuerpo
serum
tipo de anticuerpo
primary antibodies
clon
polyclonal
reactividad de especies
mouse
reactividad de especies (predicha por homología)
rat (based on 100% sequence homology), human (based on 100% sequence homology)
técnicas
western blot: suitable
Condiciones de envío
wet ice
modificación del objetivo postraduccional
unmodified
Descripción general
Asymmetrical dimethlarginine (ADMA) is an endogenous, L-arginine metabolite arising from the proteolysis of methylated arginine containing proteins and is a known inhibitor of nitric oxide synthase (NOS). In various studies, ADMA has been observed as having a regulatory role in cell motility and the actin cytoskeleton. Elevated levels of ADMA are associated with sporadic FSGS, coronary artery disease, hypertension, peripheral arterial occlusive disease, obesity, stroke, preeclampsia, and cardiovascular mortality/morbidity in patients with diabetic nephropathy.
Especificidad
This antibody recognizes dimethylated arginines.
Inmunógeno
KLH-conjugated linear peptide containing asymmetric dimethyl-arginine-glycine repeats.
Aplicación
Detect dimethyl-Arginine using this Anti-dimethyl-Arginine Antibody, asymmetric (ASYM25) validated for use in WB.
Calidad
Evaluated by Western Blot in PRMT1 treated and untreated MEF cell lysates.
Western Blot Analysis: 1:1,000 dilution of this antibody detected dimethyl-Arginine on 10 µg of PRMT1 treated and untreated MEF cell lysates.
Western Blot Analysis: 1:1,000 dilution of this antibody detected dimethyl-Arginine on 10 µg of PRMT1 treated and untreated MEF cell lysates.
Descripción de destino
Multiple. This antibody detects proteins containing asymmetrical dimethylated arginines.
Nota de análisis
Control
PRMT1 treated and untreated MEF cell lysates
PRMT1 treated and untreated MEF cell lysates
¿No encuentra el producto adecuado?
Pruebe nuestro Herramienta de selección de productos.
Código de clase de almacenamiento
10 - Combustible liquids
Clase de riesgo para el agua (WGK)
WGK 1
Certificados de análisis (COA)
Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Li-Ming Liu et al.
Cancer research, 79(11), 2865-2877 (2019-04-25)
C/EBPα is an essential transcription factor involved in regulating the expression or function of certain cell-cycle regulators, including in breast cancer cells. Although protein arginine methyltransferases have been shown to play oncogenic roles in a variety of cancers, little is
Li-Ming Liu et al.
Life (Basel, Switzerland), 11(8) (2021-08-28)
The protein p53 is one of the most important tumor suppressors, responding to a variety of stress signals. Mutations in p53 occur in about half of human cancer cases, and dysregulation of the p53 function by epigenetic modifiers and modifications
Yongtai Bai et al.
Molecular cell, 75(6), 1299-1314 (2019-07-30)
MRE11 nuclease forms a trimeric complex (MRN) with RAD50 and NBS1 and plays a central role in preventing genomic instability. When DNA double-strand breaks (DSBs) occur, MRN is quickly recruited to the damage site and initiates DNA end resection; accordingly
Minghao Yang et al.
Cell death & disease, 13(9), 815-815 (2022-09-24)
Osteosarcoma (OS), the most common primary malignancy of the bone, has a poor prognosis due to its high mortality rate and high potential for metastasis. Thus, it is urgently necessary to explore functional molecular targets of therapeutic strategies for osteosarcoma.
Gang Ren et al.
Scientific reports, 9(1), 6688-6688 (2019-05-02)
One third of newly diagnosed breast cancers in the US are early-stage lesions. The etiological understanding and treatment of these lesions have become major clinical challenges. Because breast cancer risk factors are often linked to aberrant nitric oxide (NO) production
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico